Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: The M.D. Anderson experience, with long-term follow-up
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/11/12/1597/19478041/11-12-1597.pdf
Reference20 articles.
1. Polychemotherapy for early breast cancer: An overview of the randomised trials;Lancet,1998
2. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer;Fisher;J Natl Cancer Inst,1997
3. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.
4. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer;Levine;J Clin Oncol,1998
5. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin. fluorouracil, and vincristine versus cyclophosphamide, methotrexate. and fluorouracil: Final report after a 16-year median follow-up duration;Misset;J Clin Oncol,1996
Cited by 53 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Outcomes of older adults with early-stage triple-negative breast cancer (TNBC) receiving chemotherapy: a single-institution experience;Breast Cancer Research and Treatment;2024-06-25
2. Predicting the Survival Benefit of Radiotherapy in Elderly Breast Cancer Patients: A Population-Based Analysis;Journal of Surgical Research;2024-05
3. Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor–Positive, Node-Positive Breast Cancer;JAMA Oncology;2020-10-01
4. Individualizing the Approach to the Older Woman with Triple-Negative Breast Cancer;Triple-Negative Breast Cancer;2017-11-01
5. Cardiac Complications;Holland-Frei Cancer Medicine;2017-02-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3